Press Releases

Date Title and Summary Additional Formats
Toggle Summary Marinus Pharmaceuticals to Present at the UBS Global Healthcare Conference
RADNOR, Pa. , May 14, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that Christopher M....
View HTML
Toggle Summary Marinus Pharmaceuticals Provides Business Update and First Quarter 2018 Financial Results
RADNOR, Pa. , May 02, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (“Marinus” or “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update on its clinical...
View HTML
Toggle Summary Marinus Pharmaceuticals to Present at the Barclays Global Healthcare Conference
RADNOR, Pa. , March 08, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that Edward F....
View HTML
Toggle Summary Marinus Pharmaceuticals Provides Business Update and 2017 Financial Results
RADNOR, Pa. , March 06, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update on its clinical development activities...
View HTML
Toggle Summary Marinus Pharmaceuticals to Attend Upcoming Investor Conferences
RADNOR, Pa. , Feb. 07, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that members of its management team will...
View HTML
Toggle Summary Marinus Pharmaceuticals Added to NASDAQ Biotechnology Index
RADNOR, Pa., Dec. 13, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the "Company"), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that it has been selected for addition to...
View HTML
Toggle Summary Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2017 Financial Results
RADNOR, Pa., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the "Company"), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update and reported its...
View HTML
Toggle Summary Marinus Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference
RADNOR, Pa., Sept. 21, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that Edward F....
View HTML
Toggle Summary Marinus Pharmaceuticals Announces closing of Public Offering of Common Stock and full exercise of underwriter's option to purchase additional shares
RADNOR, Pa., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) ("Marinus" or the "Company") announced the closing of an underwritten public offering of 10,733,334 shares of its common stock for a public offering price of $3.75 per share....
View HTML
Toggle Summary Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
RADNOR, Pa., Sept. 15, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) ("Marinus" or the "Company") announced the pricing of an underwritten public offering of 9,333,334 shares of common stock for a public offering price of $3.75 per share....
View HTML